Insider Trading disclosures for Ikena Oncology Inc

The latest disclosure was made by Maria Koehler in Ikena Oncology Inc where a trade of 17,520 Stock Option (Right to Buy) done was reported to US exchanges on June 7, 2024.

Insider trading is the trading of a company’s securities by individuals with access to confidential or material non-public information about the company. A company is required to report trading by corporate officers, directors, or other company members with significant access to privileged information to the Securities and Exchange Commission (SEC).

Show

Client Name	Client Category	Action	Reported to Exchange	Quantity	Post Transaction Holding	Traded %	Avg. Price	Value	Security Type
Maria Koehler	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	07 Jun 2024	17,520	17,520	-		-	Stock Option (Right to Buy)
Richard Wooster	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	07 Jun 2024	17,520	17,520	-		-	Stock Option (Right to Buy)
Iain D. Dukes	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	07 Jun 2024	17,520	17,520	-		-	Stock Option (Right to Buy)
Owen P. Hughes	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	07 Jun 2024	17,520	17,520	-		-	Stock Option (Right to Buy)
David P. Bonita	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	07 Jun 2024	17,520	17,520	-		-	Stock Option (Right to Buy)
Otello Stampacchia	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	07 Jun 2024	17,520	17,520	-		-	Stock Option (Right to Buy)
Jean-Francois Formela	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	07 Jun 2024	17,520	17,520	-		-	Stock Option (Right to Buy)
Caroline Germa	Chief Medical Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	01 Mar 2024	579,100	579,100	-		-	Stock Option (Right to Buy)
Manfredi Mark	Director, President & CEO	Grant, award, or other acquisition of securities at price $ 0.00 per share.	01 Feb 2024	320,000	320,000	-		-	Stock Option (Right to Buy)
Jeffrey Ecsedy	Chief Development Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	01 Feb 2024	100,000	100,000	-		-	Stock Option (Right to Buy)
Marango Jotin	CFO & Head of Corp. Dev.	Grant, award, or other acquisition of securities at price $ 0.00 per share.	01 Feb 2024	181,000	181,000	-		-	Stock Option (Right to Buy)
Maria Koehler	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	09 Jun 2023	17,520	17,520	-		-	Stock Option (Right to Buy)
Jean-Francois Formela	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	09 Jun 2023	17,520	17,520	-		-	Stock Option (Right to Buy)
Otello Stampacchia	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	09 Jun 2023	17,520	17,520	-		-	Stock Option (Right to Buy)
David P. Bonita	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	09 Jun 2023	17,520	17,520	-		-	Stock Option (Right to Buy)
Owen Hughes	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	09 Jun 2023	17,520	17,520	-		-	Stock Option (Right to Buy)
Iain D. Dukes	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	09 Jun 2023	17,520	17,520	-		-	Stock Option (Right to Buy)
Richard Wooster	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	09 Jun 2023	17,520	17,520	-		-	Stock Option (Right to Buy)
Sergio L. Santillana	Chief Medical Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	03 Jan 2023	105,000	105,000	-		-	Stock Option (Right to Buy)
Jotin Marango	CFO & Head of Corp. Dev.	Grant, award, or other acquisition of securities at price $ 0.00 per share.	03 Jan 2023	105,000	105,000	-		-	Stock Option (Right to Buy)
Mark Manfredi	Director, President & CEO	Grant, award, or other acquisition of securities at price $ 0.00 per share.	03 Jan 2023	220,000	220,000	-		-	Stock Option (Right to Buy)
Jeffrey Ecsedy	Chief Development Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	03 Jan 2023	105,000	105,000	-		-	Stock Option (Right to Buy)
Xiaoyan Michelle Zhang	Chief Scientific Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	03 Jan 2023	105,000	105,000	-		-	Stock Option (Right to Buy)
Owen Hughes	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	15 Dec 2022	35,040	35,040	-		-	Stock Option (Right to Buy)
David P. Bonita	Director	Purchase of securities on an exchange or from another person at price $ 3.71 per share.	22 Jun 2022	23,419	1,936,097	-	3.7	86,884	Common Stock
David P. Bonita	Director	Purchase of securities on an exchange or from another person at price $ 3.55 per share.	22 Jun 2022	66,806	1,912,678	-	3.5	237,161	Common Stock
David P. Bonita	Director	Purchase of securities on an exchange or from another person at price $ 4.37 per share.	22 Jun 2022	65,965	2,002,062	-	4.4	288,267	Common Stock
David P. Bonita	Director	Purchase of securities on an exchange or from another person at price $ 5.37 per share.	22 Jun 2022	96,035	2,098,097	-	5.4	515,708	Common Stock
Maria Koehler	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	09 Jun 2022	13,419	13,419	-		-	Stock Option (Right to Buy)
Richard Wooster	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	09 Jun 2022	13,419	13,419	-		-	Stock Option (Right to Buy)
Iain D. Dukes	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	09 Jun 2022	13,419	13,419	-		-	Stock Option (Right to Buy)
David P. Bonita	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	09 Jun 2022	13,419	13,419	-		-	Stock Option (Right to Buy)
Otello Stampacchia	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	09 Jun 2022	13,419	13,419	-		-	Stock Option (Right to Buy)
Jean-Francois Formela	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	09 Jun 2022	13,419	13,419	-		-	Stock Option (Right to Buy)
Ronald C. Renaud	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	09 Jun 2022	13,419	13,419	-		-	Stock Option (Right to Buy)
Jotin Marango	CFO & Head of Corp. Dev.	Grant, award, or other acquisition of securities at price $ 0.00 per share.	25 Apr 2022	397,199	397,199	-		-	Stock Option (Right to Buy)
Mark Manfredi	Director, President & CEO	Grant, award, or other acquisition of securities at price $ 0.00 per share.	03 Feb 2022	238,900	238,900	-		-	Stock Option (Right to Buy)
Jeffrey Ecsedy	Chief Development Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	02 Feb 2022	59,360	59,360	-		-	Stock Option (Right to Buy)
Sergio L. Santillana	Chief Medical Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	02 Feb 2022	70,400	70,400	-		-	Stock Option (Right to Buy)
Maude Tessier	Chief Business Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	02 Feb 2022	40,000	40,000	-		-	Stock Option (Right to Buy)
Xiaoyan Michelle Zhang	Chief Scientific Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	02 Feb 2022	40,000	40,000	-		-	Stock Option (Right to Buy)
Richard Wooster	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	21 Jan 2022	29,200	29,200	-		-	Stock Option (Right to Buy)
Maude Tessier	Chief Business Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.51 per share.	18 Jan 2022	8,265	100,578	-	4.5	37,275	Common Stock
Maude Tessier	Chief Business Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.15 per share.	18 Jan 2022	24,606	92,313	-	4.2	102,115	Common Stock
Maude Tessier	Chief Business Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	18 Jan 2022	8,265	28,963	-		-	Stock Option (Right to Buy)
Maude Tessier	Chief Business Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	18 Jan 2022	24,606	11,186	-		-	Stock Option (Right to Buy)
Maude Tessier	Chief Business Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	18 Jan 2022	38,915	5,560	-		-	Stock Option (Right to Buy)
Maude Tessier	Chief Business Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.94 per share.	18 Jan 2022	38,915	67,707	-	2.9	114,410	Common Stock
Xiaoyan Michelle Zhang	Chief Scientific Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.14 per share.	10 Jan 2022	36	44,511	-	2.1	77	Common Stock
Xiaoyan Michelle Zhang	Chief Scientific Officer	Sale of securities on an exchange or to another person at price $ 12.00 per share.	10 Jan 2022	36	44,475	-	12	432	Common Stock

Showing 1 to 50 of 97 entries

*All Values are in $ Million

Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures

Data as reported to USA Exchanges

View All The Insider Trades disclosures

30.41% Fall from 52W High

Insider Trading disclosures for Ikena Oncology Inc

The latest disclosure was made by Maria Koehler in Ikena Oncology Inc where a trade of 17,520 Stock Option (Right to Buy) done was reported to US exchanges on June 7, 2024.

Screeners based on Insider Trading and SAST parameters